178 related articles for article (PubMed ID: 28195120)
1. β-lactam susceptibility in extended-spectrum β-lactamase-producing isolates.
Agrawal GN; Rahangdale HD; Walawalkar AW
Indian J Pathol Microbiol; 2017; 60(1):142-143. PubMed ID: 28195120
[No Abstract] [Full Text] [Related]
2. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
3. Detection of gram-negative β-lactamase producing pathogens in the clinical lab.
Thomson KS
Curr Pharm Des; 2013; 19(2):250-6. PubMed ID: 22894616
[TBL] [Abstract][Full Text] [Related]
4. Extended-spectrum beta-lactamases: a brief clinical update.
Malloy AM; Campos JM
Pediatr Infect Dis J; 2011 Dec; 30(12):1092-3. PubMed ID: 22105419
[No Abstract] [Full Text] [Related]
5. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
Ko WC; Hsueh PR
J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
[TBL] [Abstract][Full Text] [Related]
6. Emerging epidemic of metallo-beta-lactamase-mediated resistances.
Jones RN; Biedenbach DJ; Sader HS; Fritsche TR; Toleman MA; Walsh TR
Diagn Microbiol Infect Dis; 2005 Feb; 51(2):77-84. PubMed ID: 15698711
[No Abstract] [Full Text] [Related]
7. Synthesis and in vitro antibacterial properties of 2-(3-bromo-5-isoxazolylideneamino-oxy)acetamido-beta-lactam derivatives.
Sala A; Chiarino D; Napoletano M; Albini E; Carenzi A
Farmaco; 1991; 46(7-8):887-97. PubMed ID: 1793473
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
9. Quantitative relationship between sensitivity to beta-lactam antibiotics and beta-lactamase production in gram-negative bacteria--I. Steady-state treatment.
Frère JM
Biochem Pharmacol; 1989 May; 38(9):1415-26. PubMed ID: 2785796
[TBL] [Abstract][Full Text] [Related]
10. New β-lactam antibiotics and β-lactamase inhibitors.
Bush K; Macielag MJ
Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of in vitro susceptibility tests for carbapenemase-producing Gram-negative bacteria.
Sun J; Xu Y; Yu Y; Ni Y
J Med Microbiol; 2015 Jun; 64(6):620-622. PubMed ID: 25873580
[TBL] [Abstract][Full Text] [Related]
12. Defining an extended-spectrum beta-lactamase.
Livermore DM
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():3-10. PubMed ID: 18154524
[TBL] [Abstract][Full Text] [Related]
13. [Progress in regulatory mechanism for inducing β-lactamase in Gram-negative bacteria].
Xu C; Zhang T; Cai J; Yu Z; Qiu J; Yin J
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1288-1296. PubMed ID: 30152214
[TBL] [Abstract][Full Text] [Related]
14. Overcoming β-lactam resistance in Gram-negative pathogens.
Bush K
Future Med Chem; 2016 Jun; 8(9):921-4. PubMed ID: 27228233
[No Abstract] [Full Text] [Related]
15. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control.
Stürenburg E; Mack D
J Infect; 2003 Nov; 47(4):273-95. PubMed ID: 14556752
[TBL] [Abstract][Full Text] [Related]
16. The new beta-lactamases.
Jacoby GA; Munoz-Price LS
N Engl J Med; 2005 Jan; 352(4):380-91. PubMed ID: 15673804
[No Abstract] [Full Text] [Related]
17. Dissemination of IncF plasmids carrying beta-lactamase genes in Gram-negative bacteria from Nigerian hospitals.
Ogbolu DO; Daini OA; Ogunledun A; Terry Alli OA; Webber MA
J Infect Dev Ctries; 2013 May; 7(5):382-90. PubMed ID: 23669427
[TBL] [Abstract][Full Text] [Related]
18. Omission of extended spectrum β lactamases detection: are the new Clinical Laboratory Standards Institute guidelines misleading?
Chande C; Makhija S; Lilani S; Shirpurkar R; Veer P; Chivate A; Patekar P; Joshi A
Indian J Med Microbiol; 2011; 29(4):443-4. PubMed ID: 22120816
[No Abstract] [Full Text] [Related]
19. Metallo-β-lactamases: a last frontier for β-lactams?
Cornaglia G; Giamarellou H; Rossolini GM
Lancet Infect Dis; 2011 May; 11(5):381-93. PubMed ID: 21530894
[TBL] [Abstract][Full Text] [Related]
20. Convenient test using a combination of chelating agents for detection of metallo-beta-lactamases in the clinical laboratory.
Kim SY; Hong SG; Moland ES; Thomson KS
J Clin Microbiol; 2007 Sep; 45(9):2798-801. PubMed ID: 17596358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
